The objectives of this grant application are outlined in two Specific Aims: to identify and characterize antigen-specific T cells both in response to conventional antigens and in lesions of autoimmunity and, secondly, to identify and characterize novel genes expressed in stages of T cell anergy. The first specific aim takes advantage of our recently published observation that cell surface expression of CD4 is markedly increased on antigen-activated T cells and can be used to identify antigen-specific T cells from draining lymph nodes of immunized mice. It has been possible to use this marker to isolate and characterize autoantigen-specific T cells form lesions of autoimmunity (see preliminary data). [By developing GFP transgenic mice on the NOD and B6 backgrounds, we will be able to study the CD4/high T cells in adoptive transfer in modes of autoimmunity.] The second Specific Aim intends to [identify and characterize a set of """"""""anergy associated genes"""""""" identified by the technique of differential display (see preliminary data).] By identifying and characterizing such genes and or their products, it may be possible to study mechanisms of anergy induction. Additionally, """"""""anergy-specific"""""""" genes will be used as markers to study [T cells in vivo in various models of tolerance or induced unresponsiveness in animal models of immunotherapy and/or transplantation tolerance. Using the GFP transgenic T cells in adoptive transfer will allow isolation and characterization of immunomodulated T cells from the recipient mice.] Utilizing recently developed techniques of retroviral-mediated transduction of murine T cells should allow functional analysis of the new genes described above found in states of T cell anergy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA065237-12
Application #
6172466
Study Section
Immunological Sciences Study Section (IMS)
Program Officer
Mccarthy, Susan A
Project Start
1989-04-01
Project End
2004-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
12
Fiscal Year
2000
Total Cost
$245,145
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Levin, Aron M; Bates, Darren L; Ring, Aaron M et al. (2012) Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484:529-33
Junttila, Ilkka S; Creusot, Remi J; Moraga, Ignacio et al. (2012) Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 8:990-8
Lin, Jack T; Stein, Emily A; Wong, Michael T et al. (2012) Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis. Clin Immunol 142:127-38
Whiting, Chan C; Su, Leon L; Lin, Jack T et al. (2011) GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness. FEBS J 278:47-58
Lin, Jack T; Lineberry, Neil B; Kattah, Michael G et al. (2009) Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. J Immunol 182:5919-28
Lineberry, Neil B; Su, Leon L; Lin, Jack T et al. (2008) Cutting edge: The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy. J Immunol 181:1622-6
Lineberry, Neil; Su, Leon; Soares, Luis et al. (2008) The single subunit transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane. J Biol Chem 283:28497-505
Fathman, C Garrison; Lineberry, Neil B (2007) Molecular mechanisms of CD4+ T-cell anergy. Nat Rev Immunol 7:599-609
Su, Leon; Lineberry, Neil; Huh, Yul et al. (2006) A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes. J Immunol 177:7559-66
Ermann, Joerg; Hoffmann, Petra; Edinger, Matthias et al. (2005) Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 105:2220-6

Showing the most recent 10 out of 23 publications